BoneKEy Reports | Original Article
Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label study
Ian R Reid
Jacques P Brown
Naomi Levitt
José A Román Ivorra
Javier Bachiller-Corral
Ian L Ross
Guoqin Su
Oscar Antunez-Flores
R Paul Aftring
DOI:10.1038/bonekey.2013.176
Abstract
Six patients from the phase 3 trials of zoledronic acid in Paget’s disease, who had received zoledronic acid initially and had subsequently relapsed, were entered into an open re-treatment study. Following re-treatment, each patient reached similar absolute nadirs of serum alkaline phosphatase to those recorded after their first dose. No significant adverse events were reported. It is concluded that, while re-treatment of Paget’s disease with zoledronic acid is rarely needed, it is safe and effective, with no evidence of treatment resistance based on this small cohort.
This work is licensed under a
Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.